Roche Holding AG (VTX: ROG) has agreed to purchase venture capital-backed biotechnology company Tensha Therapeutics for up to $535 million.

The deal calls for Roche to pay $115 million in upfront cash and up to another $420 million that is based on the target’s future performance

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.